Prosecution Insights
Last updated: April 19, 2026
Application No. 18/119,456

FLUORINE-CONTAINING COMPOUND AND CONTRAST AGENT

Non-Final OA §112
Filed
Mar 09, 2023
Examiner
MEJIAS, SAMANTHA LEE
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
TDK Corporation
OA Round
1 (Non-Final)
50%
Grant Probability
Moderate
1-2
OA Rounds
3y 6m
To Grant
99%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allow Rate
8 granted / 16 resolved
-10.0% vs TC avg
Strong +57% interview lift
Without
With
+57.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
61 currently pending
Career history
77
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
48.3%
+8.3% vs TC avg
§102
21.7%
-18.3% vs TC avg
§112
18.0%
-22.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 16 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Receipt is acknowledged of IDS filed on 03/09/2023. Claims 1-20 are pending. Claims 2, 5, 9-10, 12-14, and 17-18 are withdrawn. Election/Restrictions Applicant's election with traverse of Species A, Formula (11) in the reply filed on 12/22/2025 is acknowledged. The traversal is on the ground(s) that the search and examination of the entire application could be made without serious burden. This is not found persuasive because searching all of the claims would require searching in numerous different classes and subclasses, as well as, a different searching focus depending on whether the product or processes are being searched. Thus, the search would pose an undue burden on the Office. The requirement is still deemed proper and is therefore made FINAL. Foreign Priority Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application. Since a certified English translation of the foreign application was not provided. The effective filing date for this application is 03/09/2023. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1 and 6-8 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection. A generic claim may define the boundaries of a vast genus of chemical compounds, and yet the question may still remain whether the specification, including original claim language, demonstrates that the applicant has invented species sufficient to support a claim to a genus. The problem is especially acute with genus claims that use functional language to define boundaries of a claimed genus. In such a case, the functional claim may simply claim a desired result, and may do so without describing species that achieve that result. But the specification must demonstrate that the applicant has made a generic invention the achieves the claimed results and do so by showing that that the applicant has invented species sufficient to support a claim to a functionally-defined genus. A description that merely renders a claimed invention obvious may not sufficiently describe the invention for the purposes of the written description requirement of 35 U.S.C. 112 (MPEP 2163 (I)). With regard to claim 1, the specification provides insufficient written description to support the broad species of connections that can be used to bind the two nitroxide radical-containing groups represented by General Formula (I) encompassed by claim 1, since there is no description of any way to bind the two nitroxide radical-containing groups other than through an identical carbon atom provided in the specification. The specification describes specific embodiments, such as compounds 11-13 PNG media_image1.png 225 521 media_image1.png Greyscale (Applicant’s specification, page 20), however all embodiments described, including those shown above, the two nitroxide radical-containing groups are bonded through an identical carbon atom, which is highlighted above. The limited number of species only showing binding through this one type of connection does not provide sufficient description for anywhere within the molecule as described in instant claim 1. The state of the art does not teach/describe two nitroxide radical-contain groups with the general formula bound together, therefor there is no clear guidance to one skilled in the art on how to bind these two groups together. The dependent claims that do not fix this issue fall therewith. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1 and 3, 4, 6-8, 11, 15-16 and 19-20 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In regard to claim 1, it is unclear why the term “in General Formula (1), R1, R2, R3, and R4 each independently represent a C1-10 alkyl group unsubstituted or substituted with a substituent containing no fluorine atoms” is in parenthesis. Thus, it is unclear if this is a limitation in the claim or just a preferred embodiment. In regard to claim 1, it is unclear what “…” implies within the formula “ -O-C(CF3)3…”. In regard to claim 3, it is unclear what “…” implies within the formula “-CH2-O-C(CF3)3…”. The dependent claims fall therewith. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAMANTHA L. MEJIAS whose telephone number is (703)756-5666. The examiner can normally be reached M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MICHAEL HARTLEY can be reached at (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /S.L.M./ Examiner, Art Unit 1618 /Michael G. Hartley/ Supervisory Patent Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Mar 09, 2023
Application Filed
Feb 11, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12576124
A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE
2y 5m to grant Granted Mar 17, 2026
Patent 12565503
CYCLIC Gd (III) COMPLEX AND PREPARATION METHOD AND USE THEREOF
2y 5m to grant Granted Mar 03, 2026
Patent 12551578
COMPOUND OR SALT THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12551576
CHEMILUMINESCENT PROBES
2y 5m to grant Granted Feb 17, 2026
Patent 12534492
METHODS AND KITS TO IMPROVE THE FLUORESCENT SIGNAL OF DMB-LABELED SIALIC ACIDS
2y 5m to grant Granted Jan 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
50%
Grant Probability
99%
With Interview (+57.1%)
3y 6m
Median Time to Grant
Low
PTA Risk
Based on 16 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month